Pharmacogenetic Testing for Predicting Methylphenidate Treatment Outcomes in Childhood Attention Deficit Hyperactivity Disorder in Turkey: Focus on Carboxylesterase 1, Latrophilin-3, and Catechol-O-Methyltransferase.

doi:10.1002/ajmg.b.33024

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Pharmacogenetic Testing for Predicting Methylphenidate Treatment Outcomes in Childhood Attention Deficit Hyperactivity Disorder in Turkey: Focus on Carboxylesterase 1, Latrophilin-3, and Catechol-O-Methyltransferase.

American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics - 1 Jul 2025

Suzer Gamli Ipek, Van Veggel Anne, Karaaslan Rabia Sevcan, Kuerec Ajla Hodzic, Marzoukah Zeina, Adak Ibrahim, Bulut Gulay, Tunc Huseyin, Hizel Candan Perry, Parlayan Cuneyd, Ekinci Ozalp, Van Schaik Ron, Akin Demet

Abstract excerpt

Pharmacogenetic studies involving Carboxylesterase 1 (CES1), Latrophilin-3 (LPHN3), and Catechol-O-methyltransferase (COMT) revealed individual differences regarding therapeutic response in children with attention deficit hyperactivity disorder (ADHD) under methylphenidate (MPH) treatment. This study aimed to evaluate MPH's association with the adverse effect status in children and its relationship with CES1,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Attention Deficit Disorder with Hyperactivity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carboxylesterase

Share to Carboxylic Ester Hydrolases

Share to Catechol O-Methyltransferase

Share to Methylphenidate

Share to Pharmacogenomic Testing

Share to Receptors, G-Protein-Coupled

Share to Receptors, Peptide

Source

Open in PubMed

Identifiers

PMID: 39868802
DOI: 10.1002/ajmg.b.33024

Genes

CES1
COMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic Testing for Predicting Methylphenidate Treatment Outcomes in Childhood Attention Deficit Hyperactivity Disorder in Turkey: Focus on Carboxylesterase 1, Latrophilin-3, and Catechol-O-Methyltransferase.PMID 39868802Read ↗

Catechol-O-methyltransferase Val158-Met polymorphism and a response of hyperactive-impulsive symptoms to methylphenidate: A replication study from South Korea.Semantic proximity Read ↗

Population Pharmacokinetics of Methylphenidate in Healthy Adults Emphasizing Novel and Known Effects of Several Carboxylesterase 1 (CES1) Variants.Semantic proximity Read ↗

Association of the catechol-O-methyltransferase polymorphism with methylphenidate response in a classroom setting in children with attention-deficit hyperactivity disorder.Semantic proximity Read ↗

Association Between 5-HTTLPR Polymorphism and Tics after Treatment with Methylphenidate in Korean Children with Attention-Deficit/Hyperactivity Disorder.Semantic proximity Read ↗

Influence of COMT (rs4680) and DRD2 (rs1076560, rs1800497) Gene Polymorphisms on Safety and Efficacy of Methylphenidate Treatment in Children with Fetal Alcohol Spectrum Disorders.Semantic proximity Read ↗

Norepinephrine transporter gene (SLC6A2) is involved with methylphenidate response in Korean children with attention deficit hyperactivity disorder.Semantic proximity Read ↗

Pharmacogenetics of Methylphenidate Response in Preschoolers With ADHDSemantic proximity Read ↗

Association of SNAP-25, SLC6A2, and LPHN3 with OROS methylphenidate treatment response in attention-deficit/hyperactivity disorder.Semantic proximity Read ↗

LPHN3 and attention-deficit/hyperactivity disorder: a susceptibility and pharmacogenetic study.Semantic proximity Read ↗

Pharmacogenetics of methylphenidate response and tolerability in attention-deficit/hyperactivity disorder.Semantic proximity Read ↗

Methylphenidate side effect profile is influenced by genetic variation in the attention-deficit/hyperactivity disorder-associated CES1 gene.Semantic proximity Read ↗

High-Dose Methylphenidate and Carboxylesterase 1 Genetic Variability in Patients With Attention-Deficit/Hyperactivity Disorder: A Case Series.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.